Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database

M García; M A Aranburu; I Palacios-Zabalza; U Lertxundi; C Aguirre

doi:10.1111/jcpt.12397

Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database

J Clin Pharm Ther. 2016 Jun;41(3):368-370. doi: 10.1111/jcpt.12397.

Authors

M García¹, M A Aranburu², I Palacios-Zabalza³, U Lertxundi⁴, C Aguirre^{1

5}

Affiliations

¹ Basque Country Pharmacovigilance Unit, Galdakao-Usansolo Hospital, Galdakao, Spain.
² Mutriku Primary Health Care, Mutriku, Spain.
³ Pharmacy Service, Galdakao-Usansolo Hospital, Galdakao, Spain.
⁴ Pharmacy Service, Araba's Mental Health Network, Vitoria-Gasteiz, Spain.
⁵ Department of Pharmacology, Faculty of Medicine, University of Basque Country, Leioa, Spain.

PMID: 27191539
DOI: 10.1111/jcpt.12397

Abstract

What is known and objective: Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance.

Case summary: A 74-year-old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal.

What is new and conclusion: A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.

Keywords: adverse drug reactions; bullous pemphigoid; gliptins.

Publication types

Case Reports